Full Press Release Details
PHILADELPHIA, May 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 16th International Congress on Neuromuscular Diseases (ICNMD) being held virtually, May 21-22 and 28-29, 2021.
ePoster Presentations:
Enhancing Delivery of Acid Alpha-Glucosidase to Skeletal Muscle in Pompe Disease: Key Challenges and Attributes of AT-GAA Presenter: Nithya Selvan, Ph.D., Amicus Therapeutics, Philadelphia, PA, USA
Efficacy and safety of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: PROPEL study Presenter: Benedikt Schoser, MD, Department of Neurology, Ludwig-Maximilians-University of Munich, Germany
The posters will be made available on the Amicus website following their respective presentations at the congress.
For more information on the 16th International Congress on Neuromuscular Diseases, please visit www.icnmd.org.
About Amicus Therapeutics
Sr. Director, Investor Relations
Head of Global Corporate Communications